Author

R. Jaskula-Sztul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

H. Chen· 4 shared A. M. Carter· 3 shared J. A. Bibb· 3 shared M. S. Mukhtar· 2 shared N. Kumar· 2 shared R. Telange· 2 shared S. Reddy· 2 shared A. Berchuck· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

H. Chen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid Carcinoma

P. Gupta, B. Herring, N. Kumar, R. Telange, S. Garcia-Buntley, T. Caceres, S. Colantonio, F. Williams, P. Kurup, A. M. Carter, D. Lin, H. Chen, B. Rose, R. Jaskula-Sztul, M. S. Mukhtar, , J. A. Bibb

This study establishes mouse models of Cdk5-driven Medullary Thyroid Carcinoma (MTC) that recapitulate human tumor aggressiveness and identifies metabolic pathway perturbations as critical for aggressive growth.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology

PKD-1 Signaling Is Required for the Maintenance of CSCs with Epithelial-mesenchymal Plasticity in Pancreatic Neuroendocrine Tumors

Y. Guo, Y. Jiang, J. B. Rose, R. Jaskula-Sztul, A. Hjelmeland, H. Chen, B. Ren

This study shows PKD-1 signaling is essential for maintaining CSCs with epithelial-mesenchymal plasticity in pNETs, suggesting it as a therapeutic target.

bioRxiv · Feb 17, 2022 · PreprintCancer Biology

Reciprocal epigenetic Sox2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer

Z. SHONIBARE, M. Monavarian, K. O'Connell, D. Altomare, A. K. Shelton, S. Mehta, R. Jaskula-Sztul, R. Phaeton, M. D. Starr, R. Whitaker, A. Berchuck, A. Nixon, R. C. Arend, N. Y. Lee, C. R. Miller, , K. Mythreye

This study identifies Sox2 as a key node regulated by opposing TGF-β superfamily signals, impacting anoikis resistance and metastasis in ovarian cancer.

bioRxiv · Jan 11, 2022Cancer Biology

Novel anti-somatostatin receptor 2 antibody-drug conjugate for neuroendocrine cancer therapy

Y. Si, S. Kim, R. Guenter, J. Ou, Y. Lu, K. Chen, J. Zhang, J. Whitt, A. M. Carter, J. A. Bibb, J. M. Markert, R. Jaskula-Sztul, L. Zhou, H. Chen, X. Liu

This study develops an anti-somatostatin receptor 2 antibody-drug conjugate (ADC) that effectively targets and kills neuroendocrine tumors with minimal toxicity.

bioRxiv · Nov 18, 2019 · PreprintBioengineering

Phosphoprotein-based Biomarkers as Predictors for Cancer Therapy

A. M. Carter, C. Tan, K. Pozo, R. Telange, R. Molinaro, A. Guo, E. De Rosa, J. O. Martinez, S. Zhang, N. Kumar, M. Takahashi, T. Wiederhold, H. K. Ghayee, S. C. Oltmann, K. Pacak, , J. A. Bibb

The paper identifies phosphoprotein biomarkers for Cdk5 activity in neuroendocrine tumors and shows their predictive value for anti-Cdk5 therapy.

bioRxiv · Jun 20, 2019Cancer Biology